Report ID: SQMIG35A3049
Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the In-Vitro Diagnostics Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading In-Vitro Diagnostics industry players.
An ever-growing incidence of chronic and infectious diseases around the world has created an increase in the demand for early detection, routine monitoring, and regular screening to maintain health and well-being in an at-risk population. The increasing level of recognition concerning the need for preventive care and wellness care led to a significant expansion of the use of new advanced technologies in the field of diagnostics.
According to SkyQuest Technology “In-Vitro Diagnostics Market By Product (Instrument & Reagent, Software and Services) By Technology (Immunoassays, Clinical Chemistry Analyzer, Molecular Diagnostics, Blood testing, Cellular analysis, Self-Monitoring Glucose Monitoring, Hematology, Microbiology and Others), By Specimen, By Region- Industry Forecast 2025-2032,” Global In-Vitro Diagnostics Market is projected to grow at a CAGR of over 4.4% by 2032, on account of urgent need for automating quantified data. Government policies that have provided financial support to the sector and the usage of artificial intelligence and automation in medical labs to reduce the occurrence of unnecessary procedural delays in getting diagnostic tests.
|
Company |
Est. Year |
Headquarters |
Revenue |
Key Services |
|
Roche Diagnostics |
1896 |
Basel, Switzerland |
USD 15.5 billion |
Core-lab diagnostics, molecular diagnostics, immunoassays, hematology, oncology & infectious-disease testing |
|
Abbott Laboratories |
1888 |
Illinois, USA |
USD 40.1 billion |
Rapid diagnostics, point-of-care tests, molecular diagnostics, immunoassays |
|
Siemens Healthineers |
2017 |
Erlangen, Germany |
USD 26 billion |
Laboratory diagnostics, POC testing, imaging-linked diagnostics, reagents |
|
Danaher Corporation |
1984 |
Washington D.C., USA |
USD 31.5 billion |
Instruments & consumables, molecular diagnostics, automated lab systems |
|
Thermo Fisher Scientific |
1956 |
Massachusetts, USA |
USD 42.9 billion |
Molecular diagnostics, genetic testing, sequencing, reagents |
|
bioMérieux |
1963 |
Lyon, France |
USD 4.7 billion |
Microbiology diagnostics, infectious-disease testing, sepsis detection |
|
Bio-Rad Laboratories |
1952 |
California, USA |
USD 2.9 billion |
Clinical diagnostics, immunohematology, QC systems, molecular diagnostics |
|
Sysmex Corporation |
1968 |
Kobe, Japan |
USD 3.5 billion |
Hematology analyzers, urinalysis, immunochemistry, lab automation |
|
Quest Diagnostics |
1967 |
New York, USA |
USD 7.7 billion |
Clinical laboratory testing services, molecular tests, cancer & infectious-disease diagnostics |
|
Qiagen |
1984 |
Venlo, Netherlands |
USD 2.2 billion |
Molecular diagnostics kits, PCR-based tests, NGS prep, companion diagnostics |
Roche Diagnostics is one of the largest and most influential diagnostic companies in the world. The company has deep experience in core laboratory systems, molecular diagnostics, immunoassays, and oncology testing.
Abbott is a leading healthcare company with a strong presence in diagnostics. Abbott provides a variety of diagnostic products, including rapid antigen testing, point-of-care testing, core laboratory testing, and molecular testing. Its i-STAT, ARCHITECT, and Alinity platforms are among the most popular options for hospitals and primary care providers.
Siemens Healthineers has created an integrated approach to clinical care by combining imaging, advanced diagnostic technology, digital health solutions, and automation into a single solution. The company offers a wide range of immunoassays, hematology tests, clinical chemistry tests, and many of its point-of-care diagnostic products are utilized within hospital laboratories.
Danaher is a diverse science-based and technology-driven conglomerate that holds numerous internationally recognized diagnostic brand names; such as Beckman Coulter, Cepheid, and Radiometer.
Thermo Fisher Scientific is a leading manufacturer of research tools, including molecular diagnostic kits, genetic testing instruments, and sequencing systems. The majority of the company's products are aimed at the life science and laboratory sectors, but Thermo Fisher also is a major player in molecular diagnostics via its PCR instruments and Next Generation Sequencing workflows and Extraction systems for DNA and RNA.
bioMérieux is a worldwide leader in clinical microbiology and the area of infectious diseases, as evidenced by their range of automated and culture methods utilized for microbial identification.
Bio-Rad Laboratories is one of the leading providers of both Clinical diagnostics and Life Sciences Research products with an emphasis on Immunohematology, Blood Typing, Quality Control products as well as Molecular Testing Solutions. Known for their consistency and accuracy in providing quality test results in the fields/areas of Clinical Laboratories, Transfusion Centers and Research Institutions.
Sysmex Corporation is a Global Leader in Hematology Diagnostics with over 40 years of experience providing Automated Blood Analyzers and Laboratory Automation Solutions. The advances within this segment provide customers with the latest technologies that offer high throughput and high accuracy for Blood Analysis.
As one of the largest Clinical Laboratory Service Providers in the world, Quest Diagnostics provides a comprehensive menu of Diagnostic Tests covering a wide array of diseases including Oncology, Cardiology, Neurology, Infectious Disease and Genetic Testing.
Qiagen is a Global Leader within the field of Molecular Diagnostics focused on Sample Preparation, PCR Testing, and Genetic Analysis Kits. Qiagen has a well-established reputation for their Innovative Technologies that assist in the identification and testing of Infectious Disease, Biomarkers for Oncology, and Tuberculosis Detection Methods.
There has been an enormous global interest in maintaining and expanding this market over time because of the importance placed on detect early disease, develop personalized treatment plans through evidence-based medicine, and manage patients more efficiently. The emergence of additional technologies that can provide diagnostic testing, additional types of medical testing available in multiple locations.
REQUEST FOR SAMPLE
Molecular diagnostics account for about 30–32% of total IVD revenue in 2024, growing fastest due to infectious-disease and genetic testing demand.
POC testing contributes approximately USD 35 billion, or 30% of total IVD revenue, with significant adoption in home and emergency settings.
Over 3 billion IVD tests are conducted annually worldwide, including clinical chemistry, immunoassay, and molecular tests.
Molecular diagnostics and next-generation sequencing (NGS) are expanding at a CAGR of 10–12%, driven by precision medicine.
Diagnostics account for about 2–3% of total healthcare spending, yet influence 60–70% of clinical decisions.
In 2024, investments in AI-enabled IVD technologies exceeded USD 2.5 billion, reflecting growing automation and analytics capabilities.
More than 1 million analyzers were installed globally by 2024, with a steady 4–5% annual increase driven by laboratory automation.
Global In-Vitro Diagnostics Market size was valued at USD 111.19 Billion in 2024 and is poised to grow from USD 116.08 Billion in 2025 to USD 163.82 Billion by 2033, growing at a CAGR of 4.4% during the forecast period (2026–2033).
F. Hoffmann-La Roche Ltd, Hologic Inc, Abbott Laboratories, Siemens Healthcare GmbH (Siemens Healthineers), Exact Sciences Corp, bioMérieux SA, QuidelOrtho Corp, Sysmex Corp, Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, Becton Dickinson, Danaher Corporation (Beckman Coulter, Cepheid etc.), Illumina, DiaSorin (Luminex Corporation), Koninklijke Philips NV (Philips Healthcare), Qiagen N.V., Werfen, S.A. (Biokit S.A.), Agilent Technologies Inc, Quest Diagnostics, Revvity Inc, Mindray
The key driver of the in-vitro diagnostics (IVD) market is the increasing demand for early and accurate disease detection, monitoring, and personalized treatment, fueled by rising prevalence of chronic diseases, technological advancements, and growing adoption of diagnostic testing in healthcare systems.
A key market trend in the in-vitro diagnostics (IVD) market is the growing adoption of molecular diagnostics, point-of-care testing, and AI-driven diagnostic platforms, enabling faster, more accurate, and personalized disease detection and patient management.
North America accounted for the largest share in the in-vitro diagnostics (IVD) market, driven by advanced healthcare infrastructure, high adoption of diagnostic technologies, strong R&D investments, and the presence of leading IVD companies.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35A3049
sales@skyquestt.com
USA +1 351-333-4748